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Introduction {#sec1}
============

To maintain their cellular identity, embryonic stem cells (ESCs) utilize a network of core transcription factors and chromatin remodeling enzymes that bind and regulate pluripotency genes and differentiation genes in response to developmental signaling ([@bib16]). The Nucleosome Remodeling and Deacetylase (NuRD) complex is unique among chromatin regulators because it couples ATP-dependent nucleosome remodeling activity with histone modification (deacetylase) activity ([@bib27], [@bib28], [@bib30], [@bib33]). NuRD alters nucleosome occupancy to block the binding of transcriptional machinery at gene promoters, thus functioning primarily as a co-repressor ([@bib7], [@bib32]). In addition, mice deleted for the *Mbd3* gene, which encodes a NuRD subunit important for NuRD targeting and assembly, are nonviable ([@bib13]). ESCs derived from *Mbd3*-null mouse embryos do not differentiate and are capable of self-renewal in culture in the absence of leukemia inhibitory factor (LIF) ([@bib15]). *Mbd3* was subsequently shown to be important for differentiation and development through silencing of pluripotency genes ([@bib21]), functioning in part by deacetylation of H3K27 ([@bib20]).

MBD3 was originally identified as a member of the methyl-CpG binding domain (MBD) family of proteins ([@bib12]). However, unlike MBD members MECP2 and MBD1, 2, and 4, MBD3 does not bind methylated DNA ([@bib12], [@bib34]). Three MBD3 isoforms (MBD3A, B, and C) are expressed in mouse ESCs, and only MBD3A has a full-length MBD ([@bib15]). Thus, the possibility exists for formation of multiple NuRD complexes of varying subunit combinations and functional specificities.

Here, we have characterized a unique variant of the NuRD chromatin remodeling complex that harbors MBD3C, an ESC-specific isoform of MBD3, as well as the histone H3 binding protein WDR5. MBD3C is expressed almost exclusively in ESCs via an alternative CpG island (CGI)-containing promoter located in the second intron of the *Mbd3* gene. We further show that MBD3C contains a unique 50-amino-acid N terminus that is necessary for WDR5 interaction. MBD3C interacts with the WDR5 H3 binding pocket through an arginine-containing motif also utilized by MLL1 for WDR5 binding. RNA sequencing (RNA-seq) analysis revealed that the three MBD3 isoforms are largely redundant for gene regulation, since knockout (KO) of all three isoforms had a more severe effect on gene expression than individual KO of *Mbd3c* or simultaneous KO of *Mbd3a* and *Mbd3b*. Importantly, the WDR5-interaction domain of *Mbd3c* is critical for its gene regulatory function, suggesting that WDR5 plays critical roles in MBD3C/NuRD complex.

Results and Discussion {#sec2}
======================

MBD3C/NuRD Co-purifies with WDR5 {#sec2.1}
--------------------------------

To identify proteins co-purifying with MBD3 in ESCs, we used a cell line in which one copy of endogenous MBD3 is fused to a C-terminal 6xHis-3xFLAG tag (*Mbd3-H3F*; [@bib32]), allowing for affinity purification of MBD3A, B, and C simultaneously ([Figures 1](#fig1){ref-type="fig"}A and [S1](#mmc1){ref-type="supplementary-material"}A). Liquid chromatography-tandem mass spectrometry (LC-MS/MS) of purified MBD3 complexes identified all canonical NuRD subunits, several of which were subsequently confirmed by western blot ([Figure 1](#fig1){ref-type="fig"}B and [Table S1](#mmc2){ref-type="supplementary-material"}).Figure 1The NuRD Subunit MBD3C Co-purifies with WDR5(A) Silver stain of MBD3-H3F complex.(B) Western blot (WB) of purified complex from (A) showing interaction of MBD3 with NuRD subunits (left) and with WDR5 or MLL subunit ASH2L (right).(C) Western blots for MBD3-H3F or WDR5 upon immunoprecipitation (IP) of each. Asterisk indicates immunoglobulin G (IgG).(D) Silver stain of MBD3 complex expressing individually H3F-tagged MBD3 isoforms.(E) Western blot of purified complexes from (D) showing interaction with WDR5 and NuRD subunits.(F) WDR5 or FLAG immunoprecipitation from individually tagged MBD3C-H3F and MBD3CΔN-H3F ESCs. Asterisks indicate IgG.

Consistent with recent MS analyses of NuRD components ([@bib3]), we detected an interaction between MBD3 and the SET/MLL complex component WDR5 ([Figures 1](#fig1){ref-type="fig"}B and [S1](#mmc1){ref-type="supplementary-material"}B; [Table S1](#mmc2){ref-type="supplementary-material"}). The MLL complex is a histone methyltransferase that catalyzes methylation of H3K4, a mark found at transcriptionally active genes ([@bib2], [@bib24]). WDR5 binds the histone H3 tail in vitro and is essential for H3K4 trimethylation and MLL complex formation ([@bib6], [@bib10], [@bib22], [@bib25], [@bib29]). We did not observe any other MLL subunits co-purifying with MBD3 ([Figure 1](#fig1){ref-type="fig"}B and [Table S1](#mmc2){ref-type="supplementary-material"}), suggesting that WDR5 interacts with MBD3/NuRD independently of MLL complex. To validate these data, we performed co-immunoprecipitation (coIP) assays. Interestingly, WDR5 immunoprecipitation pulled down MBD3C, but not the more abundant isoforms, MBD3A and B ([Figure 1](#fig1){ref-type="fig"}C). These data suggest that WDR5 interacts specifically with this smallest and least characterized isoform of MBD3.

To further investigate the composition of the MBD3C/NuRD complex, we generated an ESC line expressing *Mbd3c-H3F* from a viral vector, such that only the MBD3C isoform is epitope-tagged. To this end, we first performed 5′ rapid amplification of cDNA ends (5′-RACE) to obtain the *Mbd3c* coding sequence. We found that MBD3C is translated from a start codon within intron 2 of the *Mbd3* gene, consistent with a recent report ([@bib9]). Thus, MBD3C lacks the entire MBD and contains a unique 50-amino-acid N terminus ([Figure S1](#mmc1){ref-type="supplementary-material"}C). MBD3C-H3F complexes were affinity purified ([Figure 1](#fig1){ref-type="fig"}D) and analyzed by LC-MS/MS. As expected, WDR5 co-purifies with MBD3C-H3F but not MBD3A-H3F ([Figures 1](#fig1){ref-type="fig"}E and [S1](#mmc1){ref-type="supplementary-material"}D; [Table S2](#mmc3){ref-type="supplementary-material"}). Importantly, we found that WDR5 interaction was disrupted by deletion of the unique MBD3C N terminus (MBD3CΔN; [Figures 1](#fig1){ref-type="fig"}E and [S1](#mmc1){ref-type="supplementary-material"}D), demonstrating that this domain is necessary for WDR5 binding. CoIP experiments confirmed these results ([Figure 1](#fig1){ref-type="fig"}F). Furthermore, we observed that MBD3C-H3F, MBD3A-H3F, and MBD3CΔN-H3F all co-purify with the canonical NuRD subunits ([Figures 1](#fig1){ref-type="fig"}E and [S1](#mmc1){ref-type="supplementary-material"}D; [Table S2](#mmc3){ref-type="supplementary-material"}). Together with data showing that WDR5 also co-purifies with NuRD subunits ([Figure S1](#mmc1){ref-type="supplementary-material"}B; [@bib3]) and that MBD3C co-fractionates exclusively with NuRD subunit MTA1 ([Figure S1](#mmc1){ref-type="supplementary-material"}E), these data demonstrate that MBD3C assembles into a canonical NuRD complex that also includes WDR5. Although the MBD3 MBD was previously shown to directly interact with NuRD subunits HDAC1 and MTA2 in vitro ([@bib23]), our findings suggest that HDAC1 and MTA2 can also associate with the NuRD complex by MBD-independent mechanisms in vivo. In addition, while the unique MBD3C N terminus is required for interaction with WDR5, it is dispensable for interaction with the other known NuRD subunits ([Figure S1](#mmc1){ref-type="supplementary-material"}D and [Table S2](#mmc3){ref-type="supplementary-material"}).

The WDR5 Histone H3 Binding Pocket Is Required for Interaction with MBD3C {#sec2.2}
-------------------------------------------------------------------------

To gain insight into the functions of the MBD3C-WDR5 interaction, we dissected the domains within MBD3C and WDR5 important for their interaction. WDR5 contains two binding surfaces on opposite sides of the protein, one that binds the histone H3 N-terminal tail or the SET/MLL complex subunit MLL1, and another that binds both the SET/MLL subunit RBBP5 ([Figure 2](#fig2){ref-type="fig"}A; [@bib18], [@bib19], [@bib26]) and long noncoding RNAs ([@bib31]). To test whether MBD3C interacts with either WDR5 binding surface, we performed coIPs in 293T cells co-transfected with vectors expressing MBD3C-H3F and FLAG-tagged point mutants from both binding surfaces of WDR5: D107A on the H3K4/MLL1 binding surface and F266A, K250A, and R181A on the RBBP5/RNA binding surface ([@bib31]). We found that the F266A, K250A, and R181A mutants of WDR5 co-immunoprecipitate with antibodies recognizing endogenous MBD3 ([Figure 2](#fig2){ref-type="fig"}B). In contrast, the D107A mutant was absent from MBD3 immunoprecipitates, suggesting that MBD3C binds near or within the WDR5 H3K4/MLL1 binding pocket.Figure 2The WDR5 Histone H3 Binding Pocket Is Required to Bind MBD3C(A) PyMol depiction of WDR5 crystal structure (PDB: [2GNQ](pdb:2GNQ){#intref0020}) showing the H3K4/MLL1 (left) and RBBP5 (right) binding pockets. Residues individually mutated to alanine ([@bib31]) are shown in magenta. Residues necessary for MLL1 R3761 or histone H3 R2 binding are shown in orange.(B) CoIPs with MBD3 antibody from 293T cells co-transfected with expression vectors carrying MBD3C-H3F and indicated FLAG-tagged WDR5 mutants.(C) Schematic of *Mbd3c* N-terminal mutant constructs used in (D) and (E).(D--F) CoIPs with MBD3 antibody in 293T cells performed as in (B), using V5-tagged WDR5 constructs and H3F-tagged MBD3 constructs. For "C41-50−MBD3A," MBD3C amino acids 41--50 were fused to the N terminus of the MBD3A isoform.(G) Alignment of the MBD3C N terminus with WDR5-binding regions of mouse MLL1, KANSL1, and histone H3.

To extend these findings, we generated a series of truncation mutants of the 50-amino-acid MBD3C N terminus to pinpoint the residues necessary for binding ([Figure 2](#fig2){ref-type="fig"}C). Deletion of the first 40 amino acids of H3F-tagged MBD3C did not disrupt the interaction with V5-tagged WDR5 ([Figure 2](#fig2){ref-type="fig"}D). However, upon deletion of amino acids 41--50 of MBD3C, interaction with WDR5 was completely lost ([Figure 2](#fig2){ref-type="fig"}E), as we observed for MBD3C mutants lacking amino acids 1--50 ([Figures 1](#fig1){ref-type="fig"}E, 1F, and [2](#fig2){ref-type="fig"}D). Furthermore, an N-terminal fusion of amino acids 41--50 to the MBD3A isoform was sufficient to allow MBD3A to bind WDR5 ([Figure 2](#fig2){ref-type="fig"}F). These data demonstrate that amino acids 41--50 of MBD3C mediate WDR5 binding (see also [Figure S1](#mmc1){ref-type="supplementary-material"}B).

MLL1, KANSL1, and histone H3 all bind the same domain on WDR5 via a 2-amino-acid alanine-arginine (AR) motif present on each protein ([@bib6], [@bib11], [@bib19], [@bib22], [@bib25], [@bib26], [@bib8]; [Figures 2](#fig2){ref-type="fig"}A and 2G). MBD3C contains an AR dipeptide within its N-terminal WDR5 binding domain (A42-R43; [Figure 2](#fig2){ref-type="fig"}G), which we hypothesized to be necessary for WDR5 binding. Confirming our hypothesis, an R43A mutant of MBD3C failed to pull down WDR5 ([Figure 2](#fig2){ref-type="fig"}E). Together, these data indicate that MBD3C, histone H3, and MLL1 use a common motif to bind the same surface of WDR5. We observed slightly reduced MBD3C protein levels in cells expressing mutants of MBD3C or WDR5 that disrupt MBD3C-WDR5 binding ([Figures 2](#fig2){ref-type="fig"}D and 2E), raising the possibility that interaction with WDR5 plays a role in stabilizing MBD3C.

*Mbd3c* Expression Is Largely Restricted to Pluripotent Stem Cells {#sec2.3}
------------------------------------------------------------------

The *Mbd3c* isoform appears to be highly expressed only in ESCs, as it is absent or weakly expressed in mouse embryonic fibroblasts (MEFs) and all adult tissues tested ([Figures S1](#mmc1){ref-type="supplementary-material"}A and [S2](#mmc1){ref-type="supplementary-material"}A). To determine when *Mbd3c* expression is lost during differentiation, we subjected ESCs to a 10-day embryoid body (EB) differentiation time course. We observed that MBD3C protein was lost between days 4 and 6 of the time course with kinetics similar to loss of OCT4 protein during differentiation ([Figure 3](#fig3){ref-type="fig"}A).Figure 3*Mbd3c* Is Dispensable for ESC Differentiation(A) Western blots from ESCs differentiated over 10 days. Actin serves as a loading control.(B) Western blots from primary MEFs reprogrammed to iPSCs.(C) Schematic of the *Mbd3* gene showing the sequence and location of the *Mbd3c* promoter CpG island (red bar). Light-blue boxes indicate exons. CpGs tested for methylation are highlighted in red.(D) Pyrosequencing of bisulfite-converted DNA from cells collected at the indicated differentiation time points. Error bars represent the SD of three biological replicates.(E and F) Western blots of differentiating *Mbd3ab* and *Mbd3abc* KO cells (E) and two clonal *Mbd3c* KO lines (F). WT, wild-type.

Next, we tested whether *Mbd3c* expression was restored upon reprogramming of differentiated cells to induced pluripotent stem cells. Primary MEFs were infected with doxycycline (dox)-inducible lentiviruses expressing reprogramming factors OCT4, SOX2, and KLF4 marked with an mCherry reporter (OSK-mCherry), L-MYC, and a lentiviral EOS-EGFP reporter specifically activated in pluripotent cells ([@bib14]). Infected cells were cultured with dox for 20 days. After an additional 10 days in the absence of dox, cells were imaged and stained for alkaline phosphatase to verify silencing of OSK-mCherry and presence of ESC-like colonies ([Figures S3](#mmc1){ref-type="supplementary-material"}A and [S3](#mmc1){ref-type="supplementary-material"}B). Lysates for western blots were prepared from expanded induced pluripotent stem cell (iPSC) colonies picked at 30 days. We observed that reprogrammed iPSC colonies express *Mbd3c* ([Figure 3](#fig3){ref-type="fig"}B). These data demonstrate that *Mbd3c* expression is restored when somatic cells are reprogrammed to iPSCs.

Finally, to investigate how *Mbd3c* expression might be silenced during differentiation, we performed bisulfite pyrosequencing analysis on the *Mbd3c* promoter during an EB differentiation time course. The *Mbd3* gene contains a ∼350-bp CGI which spans exon 2 and part of intron 2, and overlaps with the sequence encoding the MBD3C N-terminal domain ([Figure 3](#fig3){ref-type="fig"}C). We measured methylation of 11 individual CpGs within the *Mbd3c* promoter and observed a large increase in methylation at all sites over the differentiation time course ([Figure 3](#fig3){ref-type="fig"}D). Methylation increased most dramatically around day 4, which corresponds to the timing of MBD3C loss during differentiation ([Figure 3](#fig3){ref-type="fig"}A). Therefore, silencing of *Mbd3c* expression during differentiation is likely due to increased methylation of the *Mbd3c* promoter CGI.

*Mbd3c* Is Dispensable for ESC Differentiation {#sec2.4}
----------------------------------------------

*Mbd3*-null ESCs exhibit pluripotency defects and are capable of self-renewal in the absence of LIF ([@bib15]). We therefore wanted to test whether the MBD3C isoform was specifically required for early stages of differentiation. We generated homozygous *Mbd3c*, *Mbd3ab*, and *Mbd3abc* KO ESCs ([Figure S2](#mmc1){ref-type="supplementary-material"}B) using CRISPR/Cas9 cleavage and error-prone DNA repair ([@bib5]). We found that *Mbd3c* KO ESCs proliferate similarly to wild-type (WT) cells. In contrast, *Mbd3ab* KO and especially *Mbd3abc* KO ESCs grow more slowly than WT ([Figures S2](#mmc1){ref-type="supplementary-material"}C and S2D), consistent with previous observations of *Mbd3*-null ESCs ([@bib15]).

Next, we tested the differentiation capacity of each *Mbd3* mutant. Consistent with previous studies ([@bib15]), we found that ESCs lacking all MBD3 isoforms (*Mbd3abc* KO) maintained expression of both OCT4 and NANOG over 9 days in medium without LIF ([Figure 3](#fig3){ref-type="fig"}E). Unlike *Mbd3abc* KOs, *Mbd3c* KOs did not show a noticeable differentiation defect ([Figure 3](#fig3){ref-type="fig"}F). ESCs expressing only *Mbd3c* (*Mbd3ab* KO) were largely defective in differentiation (although OCT4 and NANOG levels appeared slightly reduced relative to *Mbd3abc* KO lines). Since *Mbd3c* expression is lost early during differentiation ([Figures 3](#fig3){ref-type="fig"}A and 3E), *Mbd3ab* mutants are functionally equivalent to *Mbd3abc* mutants at mid- to late-differentiation time points, potentially accounting for this phenotype. We next asked whether constitutive overexpression of *Mbd3c* in the absence of MBD3A and MBD3B could allow for normal differentiation. To test this possibility, we replaced the entire *Mbd3* gene with an H3F-tagged *Mbd3c* transgene overexpressed from the CAG promoter, which is not silenced during differentiation. Differentiation proceeds normally in these cells ([Figure S2](#mmc1){ref-type="supplementary-material"}E, top panel), revealing that MBD3C can compensate for MBD3A and MBD3B when it is overexpressed. Unexpectedly, ESCs overexpressing *Mbd3cΔN* were also able to differentiate ([Figure S2](#mmc1){ref-type="supplementary-material"}E, bottom panel), in marked contrast to cells expressing *Mbd3cΔN* at endogenous levels ([Figure S2](#mmc1){ref-type="supplementary-material"}F). We conclude that *Mbd3c* is not required for differentiation but can substitute for *Mbd3a* and *Mbd3b* when overexpressed.

MBD3 Isoforms Function Redundantly in Gene Regulation {#sec2.5}
-----------------------------------------------------

Although it is dispensable for differentiation, MBD3C binds chromatin ([Figure S4](#mmc1){ref-type="supplementary-material"}) and could still be important for regulation of a subset of MBD3 target genes independently of the other MBD3 isoforms. To test this possibility, we analyzed the transcriptomes of *Mbd3* isoform-specific mutant ESCs by RNA-seq. Gene expression in *Mbd3c* KO ESCs was largely normal ([Figure 4](#fig4){ref-type="fig"}A, left panel), with expression of only 38 genes changed more than 2-fold compared with WT. Similarly, we observed relatively few genes (258) misregulated in *Mbd3ab* KO ESCs that express only *Mbd3c* ([Figure 4](#fig4){ref-type="fig"}A, right panel) compared with a much larger number (4,879) misregulated in ESCs where all *Mbd3* isoforms are deleted ([Figures 4](#fig4){ref-type="fig"}B \[left panel\] and [4](#fig4){ref-type="fig"}C). These data suggest that *Mbd3c* can largely compensate for the loss of *Mbd3a* and *Mbd3b* at shared target genes.Figure 4MBD3C Is Redundant with MBD3A and MBD3B in Regulation of Gene Expression(A and B) MA plots showing log~2~ (fold change) in gene expression in *Mbd3c* KO (A, left), *Mbd3ab* KO (A, right), *Mbd3abc* KO (B, left), and *Mbd3cΔN-ab* KO (B, right) ESCs relative to wild-type (WT). Genes shown are misregulated ≥2-fold compared with WT.(C and D) Venn diagrams showing overlap between misregulated genes in ESCs of indicated genotypes.(E and F) WDR5 binding ([@bib1]) (E) and MOF binding ([@bib17]) (F) averaged over transcription start sites (TSS) of misregulated or unchanged genes in *Mbd3abc* KO (red) and *Mbd3cΔN-ab* KO ESCs (purple).(G) Average WDR5 binding over MBD3-bound ([@bib32]), TSS-distal DNase I hypersensitive sites (DHSs) (GSM1014514).

To test whether the unique 50-amino-acid MBD3C N terminus (and thus the interaction with WDR5) is important for this compensatory effect, we also performed RNA-seq on ESCs lacking MBD3A and MBD3B and the N terminus of MBD3C (*Mbd3cΔN-ab* KO). In contrast to the relatively few genes misregulated in *Mbd3ab* KO and *Mbd3c* KO cells, we observed 2,431 genes misregulated in *Mbd3cΔN-ab* KO cells, with nearly twice as many genes upregulated as downregulated (1,577 versus 854, respectively; [Figure 4](#fig4){ref-type="fig"}B, right panel). The vast majority (∼93%) of misregulated genes overlapped with genes misregulated in *Mbd3abc* KO cells ([Figure 4](#fig4){ref-type="fig"}D), indicating that the MBD3C N terminus is largely required for MBD3C to compensate for loss of MBD3A and MBD3B. However, as *Mbd3abc* KO has a stronger phenotype than *Mbd3cΔN-ab* KO, MBD3C/NuRD may also regulate some genes independently of its N-terminal domain. Closer examination of the 2,627 genes misregulated only in *Mbd3abc* KO ESCs ([Figure 4](#fig4){ref-type="fig"}D) revealed similar, but weaker misregulation in *Mbd3cΔN-ab* KO cells in most cases that fell below our 2-fold cutoff. These data suggest that the *Mbd3cΔN* mutation is not a complete null and are consistent with our finding that MBD3CΔN can compensate for loss of MBD3A and MBD3B during ESC differentiation, but only when overexpressed ([Figures S2](#mmc1){ref-type="supplementary-material"}E and S2F).

WDR5 is a component of multiple complexes with key regulatory functions in ESCs ([@bib1], [@bib17]). *Wdr5* knockdown results in loss of ESC self-renewal ([@bib1]), precluding the use of *Wdr5* KO ESCs to compare the functions of MBD3C and WDR5 in gene regulation. However, to test whether the genes misregulated in *Mbd3c* mutant cells are targets of WDR5 and/or WDR5-associated complexes, we examined published ESC chromatin immunoprecipitation sequencing data for WDR5 and the MSL/NSL subunit MOF ([@bib1], [@bib17]). We observed considerably higher WDR5 binding at the promoter-proximal regions of genes that were misregulated in *Mbd3abc* KO and *Mbd3cΔN-ab* KO cells compared with genes that were unaffected by *Mbd3* mutations ([Figure 4](#fig4){ref-type="fig"}E), consistent with a regulatory role for WDR5 at MBD3 target genes. However, it is likely that WDR5 regulates some of these genes through mechanisms independent of MBD3C/NuRD, as we also observed higher MOF binding at genes misregulated in *Mbd3abc* KO and *Mbd3cΔN-ab* KO cells ([Figure 4](#fig4){ref-type="fig"}F). Similarly, we found that WDR5 binding is enriched at promoter-distal DNase I hypersensitive sites that are co-bound by MBD3 ([Figure 4](#fig4){ref-type="fig"}G), suggesting that WDR5 and MBD3 co-regulate target gene expression at both promoter-distal enhancers and promoters.

We have identified a variant ESC-specific NuRD complex that includes the histone H3 binding protein WDR5. While WDR5 contributes to H3K4 trimethlyation by the SET/MLL complex ([@bib1], [@bib31]) our data suggest that a WDR5-binding MBD3C/NuRD complex functions separately from SET/MLL. Consistent with these findings, we showed that MBD3C interacts with WDR5 at the same binding surface as MLL1 and histone H3, using a conserved arginine-containing motif ([@bib6], [@bib19]). As MBD3/NuRD has previously been shown to repress pluripotency genes during differentiation ([@bib21]), it is possible that MBD3C/NuRD functions to oppose SET/MLL activity.

Our data reveal an additional layer of complexity to the composition and function of chromatin remodelers in ESCs and uncover a previously unidentified function for the WDR5 protein. The WDR5 binding domain appears to be essential for MBD3C/NuRD function in ESCs, while other MBD3/NuRD complexes are recruited to the same target genes via the MBD or other binding domains. However, since the differentiation defect of *Mbd3ab* KO cells can be overcome by constitutive overexpression of *Mbd3cΔN*, WDR5 may simply enhance the chromatin binding or remodeling activities of MBD3C/NuRD. Multiple independent mechanisms likely target different NuRD complexes to overlapping targets on chromatin, where the complexes function redundantly.

Experimental Procedures {#sec3}
=======================

MBD3 Purification and LC-MS/MS {#sec3.1}
------------------------------

MBD3/NuRD complex was purified from indicated H3F-tagged ESCs as described by [@bib32]. Purified samples were separated by SDS-PAGE, and LC-MS/MS was performed as described by [@bib4].

Embryoid Body Differentiation {#sec3.2}
-----------------------------

ESCs were differentiated to EBs in suspension culture. Cells (2.5 × 10^6^) were plated in ESC medium without LIF in bacteriological plates. Cells were replated to nongelatinized cell culture plates after 3 days and harvested for western blots at the indicated time points.

RNA-Seq {#sec3.3}
-------

Total RNA was isolated from WT and mutant ESCs using TRIzol (Life Technologies), and purified with the Zymo RNA Clean and Concentrator kit. Strand-specific libraries were prepared and sequenced by Applied Biological Materials, and analyzed as described in [Supplemental Experimental Procedures](#mmc1){ref-type="supplementary-material"}.
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